Fund Holdings — Cutter Capital Management, LP

Total Portfolio Value:
$0
Total Bought:
$0
Total Sold:
$229.65M
Net Transaction:
-$229.65M
Securities
▲▼
SharesValue
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
N/aN A000$0$0—$0
Agios Pharmaceuticals, Inc.(AGIO)235,3500-235,350$6.90M$0—-$6.90M
Amgen Inc.(AMGN)50,0000-50,000$15.58M$0—-$15.58M
Arcus Biosciences, Inc.(RCUS)731,8180-731,818$5.74M$0—-$5.74M
Biogen Inc.(BIIB)113,5000-113,500$15.53M$0—-$15.53M
BridgeBio Pharma, Inc.(BBIO)390,6440-390,644$13.50M$0—-$13.50M
Bristol-Myers Squibb Company(BMY)295,0000-295,000$17.99M$0—-$17.99M
Centessa Pharmaceuticals PlcADS418,1270-418,127$6.01M$0—-$6.01M
Cytokinetics, Incorporated(CYTK)175,0000-175,000$7.03M$0—-$7.03M
Eli Lilly and Company(LLY)18,0000-18,000$14.87M$0—-$14.87M
Halozyme Therapeutics, Inc.(HALO)120,0000-120,000$7.66M$0—-$7.66M
Insmed Incorporated(INSM)186,3840-186,384$14.22M$0—-$14.22M
Madrigal Pharmaceuticals, Inc.(MDGL)24,0000-24,000$7.95M$0—-$7.95M
Newamsterdam Pharma Company
ORDINARY SHARES
221,1520-221,152$4.53M$0—-$4.53M
Perrigo Company plcSHS(PRGO)479,5170-479,517$13.45M$0—-$13.45M
Roivant Sciences Ltd.SHS(ROIV)1,300,0000-1,300,000$13.12M$0—-$13.12M
Royalty Pharma plcCL A(RPRX)356,8940-356,894$11.11M$0—-$11.11M
Summit Therapeutics Inc.(SMMT)400,0000-400,000$7.72M$0—-$7.72M
Tarsus Pharmaceuticals, Inc.(TARS)205,0000-205,000$10.53M$0—-$10.53M
Teva Pharmaceutical Industries LimitedADS(TEVA)801,8060-801,806$12.32M$0—-$12.32M
Ultragenyx Pharmaceutical Inc.(RARE)379,3030-379,303$13.73M$0—-$13.73M
Verona Pharma PlcADS160,0000-160,000$10.16M$0—-$10.16M
Page 1 of 1
Cutter Capital Management, LP — 13F Holdings — Q2 2025 | TickerTrail